Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present RepliCel Life Sciences Inc. (OTC: REPCF).

Full DD Report for REPCF

You must become a subscriber to view this report.


Recent News from (OTC: REPCF)

RepliCel Life Sciences Announces Signed Licensing and Co-Development Deal for Greater China
Skin rejuvenation and tendon regeneration products to be commercialized in Greater China in partnership with YOFOTO ( China ) Health Industry Co. Ltd VANCOUVER and NINGBO, Zhejiang Province , China , July 11, 2018 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) (T...
Source: PR Newswire
Date: July, 11 2018 06:00
RepliCel Life Sciences Now Finalizing its Strategic Investment Partnership with China-based YOFOTO
RepliCel Life Sciences Now Finalizing its Strategic Investment Partnership with China-based YOFOTO Canada NewsWire VANCOUVER and NINGBO, Zhejiang Province, China, May 2, 2018 A revised binding term sheet reflects improved terms, and positions the parties for closing the tra...
Source: Canada Newswire
Date: May, 02 2018 06:00
RepliCel CEO Provides 2018 Shareholder Update
RepliCel CEO Provides 2018 Shareholder Update Canada NewsWire VANCOUVER, Jan. 25, 2018 With a new Asian partnership and 2017 deliverables met, RepliCel is primed and ready for expansion VANCOUVER , Jan. 25, 2018 /CNW/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) (T...
Source: Canada Newswire
Date: January, 25 2018 06:00
RepliCel Life Sciences Lands Commitment for Key Investment Partnership
RepliCel Life Sciences Lands Commitment for Key Investment Partnership Canada NewsWire VANCOUVER and NINGBO, Zhejiang Province, China, Jan. 16, 2018 YOFOTO ( China ) Health Industry Co. Ltd to Invest in Becoming RepliCel's Strategic Partner for Greater China Terms In...
Source: Canada Newswire
Date: January, 16 2018 06:00
RepliCel Life Sciences Successfully Closes Financing
RepliCel Life Sciences Successfully Closes Financing Canada NewsWire VANCOUVER, Oct. 19, 2017 Shareholders commit to non-brokered private placement in clear support of the Company's partnership strategy /NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR ...
Source: Canada Newswire
Date: October, 19 2017 17:00
RepliCel Retains Hybrid Financial for Investor Relations
RepliCel Retains Hybrid Financial for Investor Relations Canada NewsWire VANCOUVER, Sept. 22, 2017 VANCOUVER , Sept. 22, 2017 /CNW/ - RepliCel Life Sciences Inc. (OTCQB:REPCF) (TSXV:RP) (FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technol...
Source: Canada Newswire
Date: September, 22 2017 20:24
RepliCel's Partnership Initiatives Mature into Licensing Negotiations
RepliCel's Partnership Initiatives Mature into Licensing Negotiations Canada NewsWire VANCOUVER, Sept. 13, 2017 Due diligence and confidential discussions now moving into negotiations for products in both the tendon repair and aesthetics franchises VANCOUVER , Sept. 13...
Source: Canada Newswire
Date: September, 13 2017 06:00
RepliCel Showcases First Fully-Functional Prototypes of its Next-Generation Dermal Injector
Delivery of RepliCel's patented prototypes kick-starts functional testing, matures licensing discussions, and confirms commercialization schedule VANCOUVER , Sept. 7, 2017 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (FRA:P6P2) ("RepliCel" or the "Company"),...
Source: PR Newswire
Date: September, 07 2017 06:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-12N/A0.2854N/AN/A0
2018-12-110.28550.28540.28550.28541,430
2018-12-100.27590.28770.28770.27592,100
2018-12-070.2960.280.296970.278718,120
2018-12-060.30090.300.30090.293715,500

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-112001,43013.9860Cover
2018-12-102,0002,10095.2381Short
2018-12-0711,97018,12066.0596Short
2018-12-0465011,5615.6224Cover
2018-11-307,2007,200100.0000Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on REPCF.


About RepliCel Life Sciences Inc. (OTC: REPCF)

Logo for RepliCel Life Sciences Inc. (OTC: REPCF)

RepliCel Life Sciences Inc. is developing autologous cell therapies to treat conditions including chronic tendon injuries, pattern baldness and UV damaged and aging skin. All products are based on RepliCel s innovative technology which utilizes cells isolated from a patient s healthy hair follicles. Specific cells are isolated, replicated, and delivered back into the patient. In , RepliCel completed three phase clinical studies including RCH for pattern baldness from Androgenetic Alopecia, RCT for chronic Achilles tendinosis, and RCS for aging and UV damaged skin. All trials successfully met their primary endpoints and provided significantly positive clinical efficacy data on secondary endpoints. Shiseido Company, the fourth largest cosmetics company in the world, has an exclusive geographic license for RCH in certain Asian countries including Japan, China, and South Korea. They are funding a clinical study in Japan. RepliCel is actively engaging potential partners for its other products. In addition to its cellular products, RepliCel has also developed a proprietary, next generation dermal injection device RCI . The device is designed for optimal delivery of RCH and RCS but represents a next gen dermal injector for use with other dermatological injection procedures.

 

 

 

Current Management

  • David Hall / Chairman of the Supervisory Board
  • Robert L Buckler / CEO
  • Tom Kordyback / CFO
  • Rolf Hoffman / Chief Med. Officer
  • Kevin McElwee / Chief Scientific Officer
  • Lori McLellan / Other
  • David Hall / Independent Director, Audit Committee Member
  • Peter Lewis / Independent Director, Audit Committee Member
  • Geoff MacKay / Independent Director, Audit Committee Member
  • Hugh Rogers /

Current Share Structure

  • Market Cap: $6,638,624 - 03/16/2018
  • Issue and Outstanding: 21,442,584 - 01/08/2018

 


Recent Filings from (OTC: REPCF)

Annual and transition report of foreign private issuers under sections 13 or 15(d)
Filing Type: 20-FFiling Source: edgar
Filing Date: May, 11 2018
Post-effective amendment to an S-8 filing
Filing Type: S-8 POSFiling Source: edgar
Filing Date: May, 07 2018
Notification that form 20-F will be submitted late
Filing Type: NT 20-FFiling Source: edgar
Filing Date: May, 07 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 02 2018
Notification that form 20-F will be submitted late
Filing Type: NT 20-FFiling Source: edgar
Filing Date: May, 01 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: January, 25 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: January, 16 2018
Amendment to a previously filed 20-F
Filing Type: 20-F/AFiling Source: edgar
Filing Date: January, 12 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: November, 30 2017
Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(6) under the Act
Filing Type: DFiling Source: edgar
Filing Date: October, 26 2017

 

 


Daily Technical Chart for (OTC: REPCF)

Daily Technical Chart for (OTC: REPCF)


Stay tuned for daily updates and more on (OTC: REPCF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: REPCF)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in REPCF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of REPCF and does not buy, sell, or trade any shares of REPCF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/